Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and concurrent oral medications. Data Sources: PubMed was searched (to December 5, 2011 ...

Diabetes Care. 2006;29(2):435-449.

Background: Glucagon-like peptide-1(7–36)amide (GLP-1) retards gastric emptying, reduces food intake, and inhibits antroduodenal and stimulates pyloric motility. Aims: To assess the effects of ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in ...

Liraglutide and semaglutide reduce alcohol intake, cutting it by nearly two-thirds within four months of treatment.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are tied to a reduction in alcohol intake, according to a research ...

Children who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 ...

GLP-1 receptor agonists are reshaping obesity care. OHE highlights access challenges, prescribing policy, and how patient and ...

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has gained attention in various research studies ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in adults with severe mental illness, as well as having positive effects on ...

People taking semaglutide or liraglutide reduced their alcohol consumption by two-thirds within four months, according to results recently published in the journal Diabetes, Obesity and Metabolism.

Glucagon-like peptide-1 receptor agonists improve cardiovascular outcomes and reduce mortality in patients with type 2 ...